The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...

In a report released on February 5, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...

The company expects 2025 adjusted profit to be in the range of $8.15 to $8.35 per share, compared with the average of ...